Research & Literature

Cardiovascular disease in adult survivors of childhood cancer.

Lipshultz SE, Franco VI, Miller TL, et al.

Annual review of medicine 2015; (66()):161-76 doi:10.1146/annurev-med-070213-054849.

Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

Armenian SH, Hudson MM, Mulder RL, et al.

The Lancet. Oncology 2015; (16(3)):e123-36.

Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.

Cardinale D, Colombo A, Bacchiani G, et al.

Circulation 2015; (131(22)):1981-8 doi:10.1161/CIRCULATIONAHA.114.013777.

Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF).

Lala A, McNulty SE, Mentz RJ, et al.

Circulation. Heart failure 2015; (8(4)):741-8 doi:10.1161/CIRCHEARTFAILURE.114.001957.

Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.

Feijen EA, Leisenring WM, Stratton KL, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015; (33(32)):3774-80 doi:10.1200/JCO.2015.61.5187.

Management of Patients Admitted with Acute Decompensated Heart Failure.

Krim SR, Campbell PT, Desai S, et al.

Ochsner journal 2015; (15(3)):284-9.

The Utility of Point-of-Care Biomarkers to Detect Cardiotoxicity During Anthracycline Chemotherapy: A Feasibility Study.

Lenihan DJ, Stevens PL, Massey M, et al.

Journal of cardiac failure 2016; (22(6)):433-8.

Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial.

Xue K, Gu JJ, Zhang Q, et al.

Oncotarget 2016; (7(22)):32519-31 doi:10.18632/oncotarget.8685.

Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis.

Abdel-Qadir H, Ong G, Fazelzad R, et al.

Annals of oncology : official journal of the European Society for Medical Oncology 2017; (28(3)):628-633 doi:10.1093/annonc/mdw671.

Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis.

Burnett H, Earley A, Voors AA, et al.

Circulation. Heart failure 2017; (10(1)) doi:10.1161/CIRCHEARTFAILURE.116.003529.

Disease management in the treatment of patients with chronic heart failure who have universal access to health care: a randomized controlled trial.

Kalter-Leibovici O, Freimark D, Freedman LS, et al.

BMC medicine 2017; (15(1)):90 doi:10.1186/s12916-017-0855-z.

Chemotherapy-induced cardiotoxicity in children.

Bansal N, Amdani S, Lipshultz ER, Lipshultz SE

Expert opinion on drug metabolism & toxicology 2017; (13(8)):817-832 doi:10.1080/17425255.2017.1351547.

Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.

Gujral DM, Lloyd G, Bhattacharyya S

Breast (Edinburgh, Scotland) 2018; (37()):64-71 doi:10.1016/j.breast.2017.10.010.

In-Depth Insight Into the Mechanisms of Cardiac Dysfunction in Patients With Childhood Cancer After Anthracycline Treatment Using Layer-Specific Strain Analysis.

Yazaki K, Takahashi K, Shigemitsu S, et al.

Circulation journal : official journal of the Japanese Circulation Society 2018; (82(3)):715-723 doi:10.1253/circj.CJ-17-0874.

Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.

Henriksen PA

Heart (British Cardiac Society) 2018; (104(12)):971-977 doi:10.1136/heartjnl-2017-312103.

Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology.

Kostakou PM, Kouris NT, Kostopoulos VS, et al.

Heart failure reviews 2019; (24(1)):91-100 doi:10.1007/s10741-018-9731-y.

Contemporary Role of Echocardiography for Clinical Decision Making in Patients During and After Cancer Therapy.

Liu J, Banchs J, Mousavi N, et al.

JACC. Cardiovascular imaging 2018; (11(8)):1122-1131 doi:10.1016/j.jcmg.2018.03.025.

Usefulness of Global Longitudinal Strain for Early Identification of Subclinical Left Ventricular Dysfunction in Patients With Active Cancer.

Laufer-Perl M, Derakhshesh M, Milwidsky A, et al.

The American journal of cardiology 2018; (122(10)):1784-1789 doi:10.1016/j.amjcard.2018.08.019.

Late-onset cardiomyopathy among survivors of childhood lymphoma treated with anthracyclines: a systematic review.

Benetou DR, Stergianos E, Geropeppa M, et al.

Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2019; (60(3)):152-164 doi:10.1016/j.hjc.2018.09.004.

Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Denlinger CS, Sanft T, Baker KS, et al.

Journal of the National Comprehensive Cancer Network : JNCCN 2018; (16(10)):1216-1247 doi:10.6004/jnccn.2018.0078.

Recovery from left ventricular dysfunction was associated with the early introduction of heart failure medical treatment in cancer patients with anthracycline-induced cardiotoxicity.

Ohtani K, Fujino T, Ide T, et al.

Clinical research in cardiology : official journal of the German Cardiac Society 2019; (108(6)):600-611 doi:10.1007/s00392-018-1386-0.

Ferroptosis as a target for protection against cardiomyopathy.

Fang X, Wang H, Han D, et al.

Proceedings of the National Academy of Sciences of the United States of America 2019; (116(7)):2672-2680 doi:10.1073/pnas.1821022116.

Prognostic Significance of Longitudinal Clinical Congestion Pattern in Chronic Heart Failure: Insights From TIME-CHF Trial.

Simonavičius J, Sanders van-Wijk S, Rickenbacher P, et al.

The American journal of medicine 2019; (132(9)):e679-e692 doi:10.1016/j.amjmed.2019.04.010.

Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer.

Guglin M, Krischer J, Tamura R, et al.

Journal of the American College of Cardiology 2019; (73(22)):2859-2868 doi:10.1016/j.jacc.2019.03.495.

Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis.

Oikonomou EK, Kokkinidis DG, Kampaktsis PN, et al.

JAMA cardiology 2019; (4(10)):1007-1018 doi:10.1001/jamacardio.2019.2952.

Case of Anthracycline-induced Cardiogenic Shock: A Call to Optimize Modifiable Cardiac Risk Factors Prior to Chemotherapy.

Gabriel A, Stringer B, Hadfield MJ, Madady M

Cureus 2019; (11(6)):e4961 doi:10.7759/cureus.4961.

Echocardiographic Assessment of Cardiac Function in Pediatric Survivors of Anthracycline-Treated Childhood Cancer.

Slieker MG, Fackoury C, Slorach C, et al.

Circulation. Cardiovascular imaging 2019; (12(12)):e008869 doi:10.1161/CIRCIMAGING.119.008869.

Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction.

Demissei BG, Hubbard RA, Zhang L, et al.

Journal of the American Heart Association 2020; (9(2)):e014708 doi:10.1161/JAHA.119.014708.

Heart Failure in Relation to Anthracyclines and Other Chemotherapies.

Agunbiade TA, Zaghlol RY, Barac A

Methodist DeBakey cardiovascular journal 2019; (15(4)):243-249 doi:10.14797/mdcj-15-4-243.

Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.

Sokos GG, Raina A

Vascular health and risk management 2020; (16()):41-51 doi:10.2147/VHRM.S197291.

Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper.

Neuendorff NR, Loh KP, Mims AS, et al.

Blood advances 2020; (4(4)):762-775 doi:10.1182/bloodadvances.2019000955.

Mitochondrial Determinants of Doxorubicin-Induced Cardiomyopathy.

Wallace KB, Sardão VA, Oliveira PJ

Circulation research 2020; (126(7)):926-941 doi:10.1161/CIRCRESAHA.119.314681.

Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?

Murabito A, Hirsch E, Ghigo A

Frontiers in cardiovascular medicine 2020; (7()):35 doi:10.3389/fcvm.2020.00035.

Cardiotoxicity of Anthracyclines.

Cardinale D, Iacopo F, Cipolla CM

Frontiers in cardiovascular medicine 2020; (7()):26 doi:10.3389/fcvm.2020.00026.

Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment.

Saleh Y, Abdelkarim O, Herzallah K, Abela GS

Heart failure reviews 2021; (26(5)):1159-1173 doi:10.1007/s10741-020-09968-2.

Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.

Lyon AR, Dent S, Stanway S, et al.

European journal of heart failure 2020; (22(11)):1945-1960 doi:10.1002/ejhf.1920.

Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).

Čelutkienė J, Pudil R, López-Fernández T, et al.

European journal of heart failure 2020; (22(9)):1504-1524 doi:10.1002/ejhf.1957.

The Role of Biomarkers in Cardio-Oncology.

Ananthan K, Lyon AR

Journal of cardiovascular translational research 2020; (13(3)):431-450 doi:10.1007/s12265-020-10042-3.

Epigenetic Changes Associated With Anthracycline-Induced Cardiotoxicity.

Tantawy M, Pamittan FG, Singh S, Gong Y

Clinical and translational science 2021; (14(1)):36-46 doi:10.1111/cts.12857.

Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.

Pudil R, Mueller C, Čelutkienė J, et al.

European journal of heart failure 2020; (22(11)):1966-1983 doi:10.1002/ejhf.2017.

Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis.

Caspani F, Tralongo AC, Campiotti L, et al.

Internal and emergency medicine 2021; (16(2)):477-486 doi:10.1007/s11739-020-02508-8.

Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy.

Thavendiranathan P, Negishi T, Somerset E, et al.

Journal of the American College of Cardiology 2021; (77(4)):392-401 doi:10.1016/j.jacc.2020.11.020.

Role of myocardial strain imaging in surveillance and management of cancer therapeutics-related cardiac dysfunction: A systematic review.

McGregor PC, Moura FA, Banchs J, Aragam JR

Echocardiography (Mount Kisco, N.Y.) 2021; (38(2)):314-328 doi:10.1111/echo.14944.

Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy.

Gregorietti V, Fernandez TL, Costa D, et al.

Cardio-oncology (London, England) 2020; (6(1)):24 doi:10.1186/s40959-020-00078-4.

Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice.

Rosano G, Quek D, Martínez F

Cardiac failure review 2020; (6()):e31 doi:10.15420/cfr.2020.23.

Effect of myocardial dysfunction in cardiac morbidity and all cause mortality in childhood cancer subjects treated with anthracycline therapy.

Toro-Salazar OH, Gillan E, Ferranti J, et al.

Cardio-oncology (London, England) 2015; (1(1)):1 doi:10.1186/s40959-015-0005-8.

Universal Definition and Classification of Heart Failure.

Bozkurt B, Coats A, Tsutsui H

Journal of cardiac failure 2021; doi:10.1016/j.cardfail.2021.01.022.

Molecular mechanisms of anthracycline cardiovascular toxicity.

Narezkina A, Narayan HK, Zemljic-Harpf AE

Clinical science (London, England : 1979) 2021; (135(10)):1311-1332 doi:10.1042/CS20200301.

An Exploration of Heart Failure Risk in Breast Cancer Patients Receiving Anthracyclines with or without Trastuzumab in Thailand: A Retrospective Study.

Yoodee J, Sookprasert A, Sanguanboonyaphong P, et al.

Clinics and practice 2021; (11(3)):484-493 doi:10.3390/clinpract11030064.

Severe Cardiac Toxicity Induced by Cancer Therapies Requiring Intensive Care Unit Admission.

Montisci A, Palmieri V, Liu JE, et al.

Frontiers in cardiovascular medicine 2021; (8()):713694 doi:10.3389/fcvm.2021.713694.

Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.

Jirkovský E, Jirkovská A, Bavlovič-Piskáčková H, et al.

Circulation. Heart failure 2021; (14(11)):e008209 doi:10.1161/CIRCHEARTFAILURE.120.008209.

Risk Factors for Anthracycline-Induced Cardiotoxicity.

Qiu S, Zhou T, Qiu B, et al.

Frontiers in cardiovascular medicine 2021; (8()):736854 doi:10.3389/fcvm.2021.736854.

Minimizing cardiac toxicity in children with acute myeloid leukemia.

Narayan HK, Getz KD, Leger KJ

Hematology. American Society of Hematology. Education Program 2021; (2021(1)):368-375 doi:10.1182/hematology.2021000268.

Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.

Herrmann J, Lenihan D, Armenian S, et al.

European heart journal 2022; (43(4)):280-299 doi:10.1093/eurheartj/ehab674.

Novel Mechanisms of Anthracycline-Induced Cardiovascular Toxicity: A Focus on Thrombosis, Cardiac Atrophy, and Programmed Cell Death.

Antoniak S, Phungphong S, Cheng Z, Jensen BC

Frontiers in cardiovascular medicine 2021; (8()):817977 doi:10.3389/fcvm.2021.817977.

A Combined Echocardiography Approach for the Diagnosis of Cancer Therapy-Related Cardiac Dysfunction in Women With Early-Stage Breast Cancer.

Esmaeilzadeh M, Urzua Fresno CM, Somerset E, et al.

JAMA cardiology 2022; (7(3)):330-340 doi:10.1001/jamacardio.2021.5881.

Prevention of chemotherapy-induced left ventricular dysfunction.

Bisceglia I, Canale ML, Cartoni D, et al.

European heart journal supplements : journal of the European Society of Cardiology 2021; (23(Suppl E)):E28-E32 doi:10.1093/eurheartj/suab085.

Role of Myocardial Strain Imaging in Cancer Therapy-Related Cardiac Dysfunction.

Chaganti BT, Negishi K, Okajima K

Current cardiology reports 2022; (24(6)):739-748 doi:10.1007/s11886-022-01692-7.

Length of hospital stay and associated factors among heart failure patients admitted to the University Hospital in Northwest Ethiopia.

Tigabe Tekle M, Bekalu AF, Tefera YG

PloS one 2022; (17(7)):e0270809 doi:10.1371/journal.pone.0270809.

Iatrogenic Arteriovenous Fistula Secondary to Percutaneous Coronary Intervention Causing Severe Decompensated Heart Failure.

Kasliwal N, Pfeiffer WB, Eidt JF, et al.

Cureus 2022; (14(8)):e27934 doi:10.7759/cureus.27934.

Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group.

de Baat EC, van Dalen EC, Mulder RL, et al.

The Lancet. Child & adolescent health 2022; (6(12)):885-894 doi:10.1016/S2352-4642(22)00239-5.

Delphi Panel Consensus Recommendations for Screening and Managing Childhood Cancer Survivors at Risk for Cardiomyopathy.

Aziz-Bose R, Margossian R, Ames BL, et al.

JACC. CardioOncology 2022; (4(3)):354-367 doi:10.1016/j.jaccao.2022.05.010.

Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial.

Negishi T, Thavendiranathan P, Penicka M, et al.

JACC. Cardiovascular imaging 2023; (16(3)):269-278 doi:10.1016/j.jcmg.2022.10.010.

Diagnosis and Management of Cancer Treatment-Related Cardiac Dysfunction and Heart Failure in Children.

Hegazy M, Ghaleb S, Das BB

Children (Basel, Switzerland) 2023; (10(1)) doi:10.3390/children10010149.

Risk factors from Framingham risk score for anthracyclines cardiotoxicity in breast cancer: A systematic review and meta-analysis.

Jin H, Xu J, Sui Z, Wang L

Frontiers in cardiovascular medicine 2023; (10()):1101585 doi:10.3389/fcvm.2023.1101585.

Global Longitudinal Strain in Cardio-Oncology: A Review.

Sławiński G, Hawryszko M, Liżewska-Springer A, et al.

Cancers 2023; (15(3)) doi:10.3390/cancers15030986.

Patient selection for mineralocorticoid receptor antagonists in heart failure with mildly reduced or preserved ejection fraction.

Vardeny O, Houle H

Pharmacotherapy 2023; (43(6)):563-569 doi:10.1002/phar.2801.

Renin-angiotensin System Antagonists and Beta-blockers in Prevention of Anthracycline Cardiotoxicity: a Systematic Review and Meta-analysis.

Avila MS, Siqueira SRR, Waldeck L, et al.

Arquivos brasileiros de cardiologia 2023; (120(5)):e20220298 doi:10.36660/abc.20220298.

Extensive Cardiac Function Analyses Using Contemporary Echocardiography in Childhood Cancer Survivors: A DCCSS LATER Study.

Merkx R, Leerink JM, Feijen ELAM, et al.

JACC. CardioOncology 2023; (5(4)):472-485 doi:10.1016/j.jaccao.2023.06.003.

Cardiac Toxicities in Oncology: Elucidating the Dark Box in the Era of Precision Medicine.

Samuel Y, Babu A, Karagkouni F, et al.

Current issues in molecular biology 2023; (45(10)):8337-8358 doi:10.3390/cimb45100526.

Superiority of left heart deformation in early anthracycline-related cardiac dysfunction detection.

Giang M N, Nguyen H H, Vo DT, et al.

Open heart 2023; (10(2)) doi:10.1136/openhrt-2023-002493.

The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer.

Di Lisi D, Madaudo C, Faro DC, et al.

Journal of cardiovascular medicine (Hagerstown, Md.) 2024; (25(3)):218-224 doi:10.2459/JCM.0000000000001589.

Features of trastuzumab-related cardiac dysfunction: deformation analysis outside left ventricular global longitudinal strain.

Nhat GM, Hai NH, Duc VT, et al.

Frontiers in cardiovascular medicine 2024; (11()):1291180 doi:10.3389/fcvm.2024.1291180.

Late cardiotoxicity related to HER2-targeted cancer therapy.

Senechal I, Andres MS, Tong J, et al.

Cardio-oncology (London, England) 2024; (10(1)):14 doi:10.1186/s40959-024-00215-3.

Early Detection and Prediction of Anthracycline-Induced Cardiotoxicity　- A Prospective Cohort Study.

Inoue K, Machino-Ohtsuka T, Nakazawa Y, et al.

Circulation journal : official journal of the Japanese Circulation Society 2024; (88(5)):751-759 doi:10.1253/circj.CJ-24-0065.

Cardio-protective effects of statins in patients undergoing anthracycline-based chemotherapy: An updated meta-analysis of randomized controlled trials.

Felix N, Nogueira PC, Silva IM, et al.

European journal of internal medicine 2024; (126()):43-48 doi:10.1016/j.ejim.2024.04.007.

Assessment of Chemotherapy-Induced Cardiac Dysfunction in Breast Cancer Patients: A Prospective Study.

Singh J, Iqbal SA, Gajula S, et al.

Cureus 2024; (16(5)):e59461 doi:10.7759/cureus.59461.

Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors.

Bostany G, Chen Y, Francisco L, et al.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2025; (43(1)):32-45 doi:10.1200/JCO.23.01779.

Prevention of anthracycline and trastuzumab-induced decline in left ventricular ejection fraction with angiotensin-converting enzyme inhibitors or angiotensin receptor blocker: a narrative systematic review of randomised controlled trials.

Lee S, Alsamarrai A, Xiao A, Wang TKM

Internal medicine journal 2024; (54(8)):1254-1263 doi:10.1111/imj.16437.

Redefining anthracycline-related subclinical cardiotoxicity: 'Absolute' and 'relative' change in longitudinal strain.

Terluk A, Stefani L, Boyd A, et al.

ESC heart failure 2024; (11(5)):3210-3221 doi:10.1002/ehf2.14884.

An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity.

Xie S, Sun Y, Zhao X, et al.

Frontiers in pharmacology 2024; (15()):1406247 doi:10.3389/fphar.2024.1406247.

Statins for the Primary Prevention of Anthracycline Cardiotoxicity: A Comprehensive Review.

Bhasin V, Vakilpour A, Scherrer-Crosbie M

Current oncology reports 2024; (26(10)):1197-1204 doi:10.1007/s11912-024-01579-6.

Anthracycline therapy induces an early decline of cardiac contractility in low-risk patients with breast cancer.

Voß F, Nienhaus F, Pietrucha S, et al.

Cardio-oncology (London, England) 2024; (10(1)):43 doi:10.1186/s40959-024-00244-y.

Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.

Rivero-Santana B, Saldaña-García J, Caro-Codón J, et al.

European heart journal 2025; (46(3)):273-284 doi:10.1093/eurheartj/ehae496.

Strain surveillance during chemotherapy to improve cardiovascular outcomes: the SUCCOUR-MRI trial.

Marwick TH, Dewar E, Nolan M, et al.

European heart journal 2024; (45(41)):4414-4424 doi:10.1093/eurheartj/ehae574.

Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD - PILOT trial.

Daniele AJ, Gregorietti V, Costa D, López-Fernández T

Cardio-oncology (London, England) 2024; (10(1)):58 doi:10.1186/s40959-024-00260-y.

Guidelines for treating heart failure.

Kittleson MM

Trends in cardiovascular medicine 2025; (35(3)):141-150 doi:10.1016/j.tcm.2024.10.002.

Preventing Cardiac Damage in Patients Treated for Breast Cancer and Lymphoma: The PROACT Clinical Trial.

Austin D, Maier RH, Akhter N, et al.

JACC. CardioOncology 2024; (6(5)):684-696 doi:10.1016/j.jaccao.2024.07.010.

Cardiotoxicity of Anthracyclines.

Balough E, Ariza A, Asnani A, Hoeger CW

Cardiology clinics 2025; (43(1)):111-127 doi:10.1016/j.ccl.2024.08.002.

Recovery of Left Ventricular Ejection Fraction in Patients With Anthracycline-Induced Cardiomyopathy: A Contemporary Cohort Study.

Itzhaki Ben Zadok O, Simitsis P, Nohria A

Journal of cardiac failure 2025; (31(9)):1379-1389 doi:10.1016/j.cardfail.2024.12.012.

Risk Assessment Prior to Cardiotoxic Anticancer Therapies in 7 Steps.

Tong J, Senechal I, Ramalingam S, Lyon AR

British journal of hospital medicine (London, England : 2005) 2025; (86(1)):1-21 doi:10.12968/hmed.2024.0632.

Effectiveness of exercise-based interventions in preventing cancer therapy-related cardiac dysfunction in patients with breast cancer: A systematic review and network meta-analysis.

Zhang D, Xiong X, Ding H, et al.

International journal of nursing studies 2025; (163()):104997 doi:10.1016/j.ijnurstu.2025.104997.

Missed or Delayed Diagnosis of Heart Disease by the General Pediatrician.

Karatza AA, Fouzas S, Gkentzi D, et al.

Children (Basel, Switzerland) 2025; (12(3)) doi:10.3390/children12030366.

Mitochondrial Dysfunction in Cardiac Diseases: Insights into Pathophysiology and Clinical Outcomes.

Ahmad SS, Ansari JA, Ansari TM, Zaidi SMH

Current cardiology reviews 2026; (22(1)):e1573403X379197 doi:10.2174/011573403X379197250417061904.

Echocardiographic parameters and risk factors for cardiomyopathy in Japanese childhood cancer survivors: A report from St. Luke's lifetime cohort study.

Ichikawa N, Hasegawa D, Nagase K, et al.

Journal of cardiology 2025; (86(5)):453-458 doi:10.1016/j.jjcc.2025.05.018.

Prevention of cancer therapy-related cardiac dysfunction and heart failure in cancer patients and survivors. A Clinical Consensus Statement of the Heart Failure Association, the European Association of Preventive Cardiology of the ESC, and the ESC Council of Cardio-Oncology.

Rakisheva A, Farmakis D, Attanasio A, et al.

European journal of heart failure 2025; (27(11)):2084-2099 doi:10.1002/ejhf.3753.

ANTHRACYCLINE-INDUCED CARDIOTOXICITY: MECHANISM AND PREVENTION.

Yeh ETH, Chang HM

Transactions of the American Clinical and Climatological Association 2025; (135()):184-195.

Alteration of cardiac energetics and mitochondrial function in doxorubicin‑induced cardiotoxicity: Molecular mechanism and prospective implications (Review).

Qing G, Huang C, Pei J, Peng B

International journal of molecular medicine 2025; (56(5)).

Risk prediction models for cancer therapy related cardiac dysfunction in patients with cancer and cancer survivors: systematic review and meta-analysis.

Gomes C, Geels J, Debray TPA, et al.

BMJ (Clinical research ed.) 2025; (390()):e084062 doi:10.1136/bmj-2025-084062.

Temporal Dynamics of Extracellular Matrix Remodeling in Anthracycline-Induced Cardiotoxicity.

Meshrkey F, Ibrahim SY, Bagchi RA, Richardson WJ

Cells 2025; (14(18)) doi:10.3390/cells14181471.

The Role of Diastolic Stress Echo and Myocardial Work in Early Detection of Cardiac Dysfunction in Women with Breast Cancer Undergoing Chemotherapy.

Sokratous S, Kyriakou M, Khattab E, et al.

Biomedicines 2025; (13(10)) doi:10.3390/biomedicines13102341.

Association of early dexrazoxane with reduced cardiotoxicity risk in sarcoma patients treated with anthracycline chemotherapy.

Jang KH, Wallins JS, Lin IH, et al.

The oncologist 2025; (30(12)) doi:10.1093/oncolo/oyaf370.

Current strategies for prevention of cancer therapy-related cardiotoxicity: pharmacological, non-pharmacological and emerging approaches.

Migliari M, Fazzini L, Campana N, et al.

Frontiers in cardiovascular medicine 2025; (12()):1668308 doi:10.3389/fcvm.2025.1668308.

Pharmacological prevention in cardio-oncology: from bench-to-bedside.

Avagimyan AA, Pogosova N, Fogacci F, et al.

Heart failure reviews 2025; (31(1)):7 doi:10.1007/s10741-025-10575-2.

Anthracyclines and the Heart: A Double-edged Sword With Therapeutic Hopes.

Alotaibi TM, Samman AM, Al Ghamdi AA, et al.

Journal of the Saudi Heart Association 2026; (38(1)):2 doi:10.37616/2212-5043.1475.

Doxorubicin-Induced Cardiotoxicity: Comprehensive Pathway Insights and Advanced Preclinical Therapeutics.

Sharma S, Parashar M, Lal K, et al.

Journal of applied toxicology : JAT 2026; (46(6)):1801-1837 doi:10.1002/jat.70131.

Review on cardioprotective strategies in the setting of chemotherapy-induced cardiotoxicity.

Dao V, Amin S, Kammaripalle T, Manning K

Cardio-oncology (London, England) 2026; (12(1)).

Cardiac Biomarkers and Multimodality Imaging in Surveillance During Oncologic Therapy: An Integrated Approach to Cardio-Oncology.

Agrawal SP, Lussier A, Patel DS, et al.

Cardiology in review 2026; doi:10.1097/CRD.0000000000001334.

Time to Personalize Surveillance for Cancer Therapy-Related Cardiac Dysfunction in HER2-Targeted Therapy: One Size Does Not Fit All.

Ebrahimi S, Namburu LV, Deswal A

Current heart failure reports 2026; (23(1)).

Doxorubicin-induced cardiotoxicity: Is ferroptosis the primary driver or a downstream amplifier?

Goswami Y, Sharma N, Navik U

EXCLI journal 2026; (25()):974-990 doi:10.17179/excli2026-9516.

Exercise for the mitigation of cancer therapy-related cardiac dysfunction in breast cancer patients treated with anthracyclines: a systematic review and meta-analysis.

Marín AJ, García-Coll MV, Moraleda EM, et al.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2026; (34(10)).